NL300820I2 - - Google Patents

Info

Publication number
NL300820I2
NL300820I2 NL300820C NL300820C NL300820I2 NL 300820 I2 NL300820 I2 NL 300820I2 NL 300820 C NL300820 C NL 300820C NL 300820 C NL300820 C NL 300820C NL 300820 I2 NL300820 I2 NL 300820I2
Authority
NL
Netherlands
Prior art keywords
hsv1
strain
hsv
tumour cells
oncolytic
Prior art date
Application number
NL300820C
Other languages
English (en)
Original Assignee
Biovex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27447756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300820(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0001475A external-priority patent/GB0001475D0/en
Priority claimed from GB0002854A external-priority patent/GB0002854D0/en
Priority claimed from GB0100288A external-priority patent/GB0100288D0/en
Priority claimed from GB0100430A external-priority patent/GB0100430D0/en
Application filed by Biovex Ltd filed Critical Biovex Ltd
Publication of NL300820I2 publication Critical patent/NL300820I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
NL300820C 2000-01-21 2016-06-14 NL300820I2 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0001475A GB0001475D0 (en) 2000-01-21 2000-01-21 Virus strains
GB0002854A GB0002854D0 (en) 2000-02-08 2000-02-08 Virus strains
GB0100288A GB0100288D0 (en) 2001-01-05 2001-01-05 Virus strains
GB0100430A GB0100430D0 (en) 2001-01-06 2001-01-06 Virus strains
PCT/GB2001/000225 WO2001053505A2 (en) 2000-01-21 2001-01-22 Herpes virus strains for gene therapy

Publications (1)

Publication Number Publication Date
NL300820I2 true NL300820I2 (nl) 2016-11-17

Family

ID=27447756

Family Applications (2)

Application Number Title Priority Date Filing Date
NL300821C NL300821I2 (nl) 2000-01-21 2016-06-14
NL300820C NL300820I2 (nl) 2000-01-21 2016-06-14

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NL300821C NL300821I2 (nl) 2000-01-21 2016-06-14

Country Status (22)

Country Link
US (12) US7223593B2 (nl)
EP (4) EP1568779A1 (nl)
JP (6) JP4810042B2 (nl)
KR (2) KR100802403B1 (nl)
CN (2) CN1418255A (nl)
AT (2) ATE282708T1 (nl)
AU (2) AU2695101A (nl)
BE (1) BE2016C033I2 (nl)
BR (3) BRPI0107736B8 (nl)
CA (2) CA2398335C (nl)
CY (2) CY2016020I2 (nl)
DE (2) DE60115600T2 (nl)
DK (2) DK1252322T4 (nl)
ES (2) ES2233600T5 (nl)
FR (1) FR16C0026I2 (nl)
GB (2) GB2375113B (nl)
HK (2) HK1047451B (nl)
IL (4) IL150677A0 (nl)
LU (2) LU93100I2 (nl)
NL (2) NL300821I2 (nl)
PT (1) PT1252322E (nl)
WO (2) WO2001053505A2 (nl)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
ATE282708T1 (de) 2000-01-21 2004-12-15 Biovex Ltd Herpes-virusstämme für die gentherapie
US20050267061A1 (en) * 2004-04-08 2005-12-01 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
AU2002306919B2 (en) 2001-03-27 2007-11-22 Tomoki Todo Viral vectors and their use in therapeutic methods
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
JP2007511216A (ja) * 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
AU2005228788B2 (en) * 2004-03-31 2010-12-02 Tomoki Todo Anticancer activity enhancer of viral therapy and method of cancer prevention or treatment
US9273326B2 (en) * 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
EP2002003B1 (en) * 2005-05-27 2015-12-30 Ospedale San Raffaele S.r.l. Gene vector comprising mi-rna
US20080008686A1 (en) * 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
US8313896B2 (en) * 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
RS54933B1 (sr) 2009-12-21 2016-10-31 Brigham & Womens Hospital Inc Vakcine herpes simpleks virusa
CN102146418B (zh) * 2010-02-09 2014-01-15 武汉滨会生物科技有限公司 重组ⅱ型单纯疱疹病毒载体及其制备方法、重组病毒、药物组合物及应用
JPWO2011101912A1 (ja) * 2010-02-19 2013-06-17 国立大学法人 東京大学 組み換えヘルペスウイルス及び組換えヘルペスウイルスを含む医薬組成物
WO2011119628A2 (en) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
DK2753355T3 (en) * 2011-09-08 2019-01-28 Univ New York ONCOLYTIC HERP SIMPLEX VIRUSES AND THERAPEUTIC APPLICATIONS THEREOF
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
CN114984062A (zh) 2012-08-30 2022-09-02 安姆根有限公司 使用单纯疱疹病毒和免疫检查点抑制剂治疗黑色素瘤的方法
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
RU2020105656A (ru) * 2013-07-17 2021-01-27 Юниверсити Оф Питтсбург- Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Нетоксичные векторы на основе впг для применений в эффективной доставке генов и комплементирующие клетки для их продуцирования
WO2015061386A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Injector and method of assembly
WO2015061389A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
EP3372236A1 (en) 2013-10-25 2018-09-12 PsiOxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
EP3082834B1 (en) 2013-12-11 2020-03-11 The General Hospital Corporation DBA Massachusetts Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
KR102496507B1 (ko) 2014-05-07 2023-02-03 암겐 인코포레이티드 충격 감소 요소들을 가진 자동 주사기
WO2015187793A1 (en) 2014-06-03 2015-12-10 Amgen Inc. Drug delivery system and method of use
KR102122463B1 (ko) 2014-10-14 2020-06-15 할로자임, 아이엔씨 아데노신 디아미네이즈-2(ada2)의 조성물, 이의 변이체 및 이를 사용하는 방법
MX2021014323A (es) 2014-10-14 2023-02-02 Amgen Inc Dispositivo de inyección de fármaco con indicadores visuales y audibles.
ES2898469T3 (es) 2014-12-19 2022-03-07 Amgen Inc Dispositivo de administración de medicamentos con sensor de proximidad
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
PT3250550T (pt) 2015-01-26 2023-08-09 Univ Ottawa Composições e métodos para sensibilização viral
WO2016133947A1 (en) 2015-02-17 2016-08-25 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
GB201505860D0 (en) 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
WO2016168601A1 (en) 2015-04-17 2016-10-20 Khalid Shah Agents, systems and methods for treating cancer
AU2016256582B2 (en) 2015-04-30 2020-10-29 Akamis Bio Limited Oncolytic adenovirus encoding a B7 protein
WO2016205429A1 (en) 2015-06-15 2016-12-22 New York University Method of treatment using oncolytic viruses
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
CN105219738A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
KR20180104597A (ko) 2015-11-07 2018-09-21 멀티비르 인코포레이티드 암 치료를 위한 종양 억제 유전자 요법 및 면역관문 봉쇄를 포함하는 조성물
ES2755717T3 (es) 2015-12-09 2020-04-23 Amgen Inc Autoinyector con tapa de señalización
IL260027B (en) 2015-12-17 2022-07-01 Psioxus Therapeutics Ltd A group b adenovirus that encodes an anti-tcr–complex antibody or particle
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
JP6959258B2 (ja) * 2016-01-08 2021-11-02 レプリミュン リミテッド 改変された腫瘍溶解性ウイルス
ES2930046T3 (es) 2016-02-19 2022-12-05 Virogin Biotech Canada Ltd Composiciones y métodos de uso de inhibidores de STAT1/3 con virus del herpes oncolíticos
EP4035711A1 (en) 2016-03-15 2022-08-03 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017165813A1 (en) 2016-03-25 2017-09-28 Periphagen, Inc. High-transducing hsv vectors
SG11201808783XA (en) 2016-04-15 2018-11-29 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
NZ746741A (en) 2016-04-15 2023-12-22 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
EP3426272A4 (en) 2016-04-26 2020-03-04 Salk Institute for Biological Studies HSV-1 ONCOLYTIC VIRUS THERAPIES THAT TARGET ALT-DEPENDENT CANCERS
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
CN115960966A (zh) 2016-04-29 2023-04-14 复诺健生物科技加拿大有限公司 在癌细胞中具有增强复制的hsv载体
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CA3032120A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
EP3490583B1 (en) 2016-08-01 2023-11-29 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CN110022889A (zh) 2016-10-03 2019-07-16 渥太华医院研究所 用于提高溶瘤rna病毒的生长、传播和溶瘤与免疫治疗效果的组合物和方法
WO2018075447A1 (en) 2016-10-19 2018-04-26 The Trustees Of Columbia University In The City Of New York Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
CN110352245A (zh) 2016-10-20 2019-10-18 高山免疫科学股份有限公司 可分泌变体免疫调节蛋白和工程化细胞疗法
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
US20200009203A1 (en) 2016-12-12 2020-01-09 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
WO2018118967A1 (en) 2016-12-21 2018-06-28 Memgen, Llc Armed replication-competent oncolytic adenoviruses
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
US20190358411A1 (en) 2017-01-17 2019-11-28 Amgen Inc. Injection devices and related methods of use and assembly
CN110546265A (zh) 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
EP3582825A1 (en) 2017-02-17 2019-12-25 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
MX2019010544A (es) 2017-03-06 2019-10-21 Amgen Inc Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion.
SG11201908058UA (en) 2017-03-07 2019-09-27 Amgen Inc Needle insertion by overpressure
KR20240005194A (ko) 2017-03-09 2024-01-11 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
AU2018235944B2 (en) 2017-03-15 2024-01-04 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
CA3053812A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
JP2020509776A (ja) 2017-03-16 2020-04-02 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ１バリアント免疫調節タンパク質及びその使用
BR112019018747A2 (pt) 2017-03-16 2020-05-05 Alpine Immune Sciences Inc proteínas imunomoduladoras variantes de cd80 e usos das mesmas
CA3052676A1 (en) 2017-03-28 2018-10-04 Amgen Inc. Plunger rod and syringe assembly system and method
SG11201908296VA (en) 2017-04-28 2019-10-30 Merck Sharp & Dohme Biomarkers for cancer therapeutics
CN106974942A (zh) * 2017-05-03 2017-07-25 武汉滨会生物科技股份有限公司 重组溶瘤ii型单纯疱疹病毒在制备抗淋巴瘤、食道癌、乳腺癌、胰腺癌药物中的应用
US11904143B2 (en) 2017-06-08 2024-02-20 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CN107354136A (zh) * 2017-06-15 2017-11-17 杭州睿可特生物科技有限公司 重组单纯疱疹病毒及其制备方法和应用
US11541183B2 (en) 2017-06-22 2023-01-03 Amgen Inc. Device activation impact/shock reduction
MX2019015479A (es) 2017-06-23 2020-02-20 Amgen Inc Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador.
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
JP2020527376A (ja) 2017-07-21 2020-09-10 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
MA49677A (fr) 2017-07-25 2021-04-21 Amgen Inc Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
SI3661954T1 (sl) 2017-08-03 2022-05-31 Amgen Inc. Muteini interlevkina-21 in postopki zdravljenja
JP2020530003A (ja) 2017-08-07 2020-10-15 アムジェン インコーポレイテッド 抗ｐｄ−ｌ１抗体及び腫瘍溶解性ウイルスでの、肝転移を伴う三種陰性乳がん又は結腸直腸がんの処置
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
CA3074901A1 (en) 2017-09-11 2019-03-14 Imba - Institut Fur Molekulare Biotechnologie Gmbh Tumor organoid model
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
MA50614A (fr) 2017-10-06 2020-08-12 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
WO2019074579A1 (en) 2017-10-09 2019-04-18 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A DRIVE ASSEMBLY AND ASSEMBLY METHOD THEREOF
JP2020536552A (ja) 2017-10-10 2020-12-17 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ−４変異型免疫調節タンパク質およびそれらの使用
TW201925223A (zh) 2017-10-18 2019-07-01 美商艾爾潘免疫科學有限公司 變異型icos 配位體免疫調節蛋白及相關組合物及方法
KR20200078483A (ko) 2017-10-27 2020-07-01 머크 샤프 앤드 돔 코포레이션 간암 치료를 위한 조성물 및 방법
WO2019090079A1 (en) 2017-11-03 2019-05-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
MA50553A (fr) 2017-11-06 2020-09-16 Amgen Inc Dispositif d'administration de médicament avec détection de positionnement et de débit
WO2019094138A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
MA50904A (fr) 2017-11-16 2020-09-23 Amgen Inc Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament
US20230101432A1 (en) 2018-01-03 2023-03-30 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
BR112020014121A2 (pt) 2018-01-12 2020-12-01 Amgen Inc. anticorpos anti-pd-1 e métodos de tratamento
WO2019152821A1 (en) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
US11897924B2 (en) * 2018-03-28 2024-02-13 Bioxodes Anticoagulant fusion proteins and uses thereof
JP2021522854A (ja) * 2018-05-01 2021-09-02 アルベルト・アインシュタイン・カレッジ・オブ・メディシンＡｌｂｅｒｔ Ｅｉｎｓｔｅｉｎ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ ＨＳＶ−２−ＤＥＬＴＡ−ｇＤ ワクチンおよびそれらの生産および使用のための方法
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
KR20210022010A (ko) 2018-06-04 2021-03-02 카리디 바이오테라퓨틱스, 인크. 바이러스 치료법의 강화를 위한 세포-기반 비히클
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
CN112243378A (zh) * 2018-06-08 2021-01-19 伊利诺伊大学理事会 用于癌症免疫疗法的重组单纯疱疹病毒
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
US20210253655A1 (en) * 2018-06-15 2021-08-19 Children's Hospital Medical Center Polypeptides, nucleic acid molecules, compositions, and related methods
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
EP3826699A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
CN109161561A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
IL281469B1 (en) 2018-09-28 2024-04-01 Amgen Inc Assembling a memory alloy ejector activation assembly for a drug delivery device
JP2022503983A (ja) 2018-10-02 2022-01-12 アムジエン・インコーポレーテツド 内力伝達を伴う薬物送達用の注入システム
CA3112214A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
CA3112355A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Drug delivery device having damping mechanism
US20210346596A1 (en) 2018-10-15 2021-11-11 Amgen Inc. Platform assembly process for drug delivery device
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
AU2019370159A1 (en) 2018-11-01 2021-04-22 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020092056A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial needle retraction
JP7329593B2 (ja) 2018-11-06 2023-08-18 カリディ・バイオセラピューティクス・インコーポレイテッド 細胞媒介性腫瘍溶解性ウイルス治療のための増強された系
EP3884041A2 (en) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
AU2019389151A1 (en) 2018-11-30 2021-06-10 Alpine Immune Sciences, Inc. CD86 variant immunomodulatory proteins and uses thereof
CA3124690A1 (en) 2018-12-27 2020-07-02 Amgen Inc. Lyophilized virus formulations
CA3176660A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
MX2021010458A (es) * 2019-03-05 2021-09-21 Amgen Inc Uso de virus oncoliticos para el tratamiento del cancer.
JP2022526094A (ja) * 2019-03-14 2022-05-23 マサチューセッツ インスティテュート オブ テクノロジー 操作された単純ヘルペスウイルス－１（ｈｓｖ－１）ベクターおよびその使用
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
WO2020219482A1 (en) 2019-04-24 2020-10-29 Amgen Inc. Syringe sterilization verification assemblies and methods
JP2022545227A (ja) 2019-08-23 2022-10-26 アムジエン・インコーポレーテツド 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
JP2023507989A (ja) * 2019-12-20 2023-02-28 クリスタル バイオテック インコーポレイテッド 気道及び／または肺への遺伝子送達のための組成物及び方法
WO2021216790A1 (en) 2020-04-22 2021-10-28 Indapta Therapeutics, Inc. Natural killer (nk) cell compositions and methods for generating same
US20220016191A1 (en) * 2020-07-16 2022-01-20 Massachusetts Institute Of Technology Simultaneous delivery of cancer treatment programs to tumor and immune cells
TW202241479A (zh) 2020-12-30 2022-11-01 美商安迅生物製藥公司 遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
IL307418A (en) 2021-05-21 2023-12-01 Amgen Inc A method for optimizing a filling recipe for a drug container
CN115707781A (zh) * 2021-08-20 2023-02-21 广东东阳光药业有限公司 Hsv病毒载体及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5163949A (en) * 1990-03-02 1992-11-17 Bonutti Peter M Fluid operated retractors
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
GB9202933D0 (en) 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
ATE228570T1 (de) 1992-03-31 2002-12-15 Arch Dev Corp Behandlung von tumorerkrankungen mit modifiziertem hsv
GB9325496D0 (en) 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9423663D0 (en) 1994-11-23 1995-01-11 Cantab Pharma Res Viral preparations, immunogens, and vaccines
NL9500216A (nl) * 1995-02-06 1996-09-02 Bio Pharma Sciences Bv Farmaceutische samenstelling voor de behandeling van herpes.
ATE324435T1 (de) * 1995-02-21 2006-05-15 Cantab Pharmaceuticals Res Ltd Virale zubereitungen, vektoren, immunogene und impfstoffe
IL118942A (en) 1995-07-27 2002-09-12 American Cyanamid Co Nonviolent viruses used as killers - tumors and vaccines
US6344445B1 (en) * 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
DE69722608T2 (de) 1996-01-25 2004-04-29 The University Court Of The University Of Glasgow, Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US5876923A (en) * 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
GB2322130B (en) 1997-02-13 2000-12-20 Secr Defence A vaccine against Simian Herpes B virus
GB9704046D0 (en) * 1997-02-27 1997-04-16 Univ Leeds Arrestable therapeutic
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
CA2323067A1 (en) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
GB9810904D0 (en) 1998-05-20 1998-07-22 Univ London Mutant herpes simplex viruses and uses thereof
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US6713067B2 (en) * 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
WO2000008051A2 (en) 1998-08-07 2000-02-17 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
WO2000040734A1 (en) * 1998-12-31 2000-07-13 Arch Development Corporation Recombinant herpes simplex virus useful for treating neoplastic disease
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
EP1190040B1 (en) 1999-06-08 2007-08-22 UAB Research Foundation Herpes simplex virus expressing interleukin-12 gene and and its use for treating cancer
US6764675B1 (en) * 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
IL131212A0 (en) * 1999-08-03 2001-01-28 Yissum Res Dev Co Recombinant virus and live-virus vaccines
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
GB9930419D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
GB0001476D0 (en) 2000-01-21 2000-03-15 Neurovex Ltd Herpes virus strains
ATE282708T1 (de) 2000-01-21 2004-12-15 Biovex Ltd Herpes-virusstämme für die gentherapie
US7063851B2 (en) 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
JP6959258B2 (ja) * 2016-01-08 2021-11-02 レプリミュン リミテッド 改変された腫瘍溶解性ウイルス

Also Published As

Publication number Publication date
JP2012072156A (ja) 2012-04-12
WO2001053506A2 (en) 2001-07-26
EP1568779A1 (en) 2005-08-31
US7537924B2 (en) 2009-05-26
BR0107737A (pt) 2002-11-19
WO2001053505A3 (en) 2001-12-27
BE2016C033I2 (nl) 2020-05-20
CN1425073A (zh) 2003-06-18
US7063835B2 (en) 2006-06-20
US8680068B2 (en) 2014-03-25
CN1418255A (zh) 2003-05-14
JP6644378B2 (ja) 2020-02-12
AU2694701A (en) 2001-07-31
GB0219030D0 (en) 2002-09-25
US10301600B2 (en) 2019-05-28
US20200032218A1 (en) 2020-01-30
AU2001226951B8 (en) 2006-10-26
CY2016021I1 (el) 2016-12-14
WO2001053505A2 (en) 2001-07-26
GB0219033D0 (en) 2002-09-25
CA2398343A1 (en) 2001-07-26
DK1252323T3 (da) 2006-04-03
KR20030032913A (ko) 2003-04-26
BRPI0107737B1 (pt) 2016-11-16
US20140154215A1 (en) 2014-06-05
DE60115600D1 (de) 2006-01-12
DK1252322T3 (da) 2005-03-14
HK1047297A1 (en) 2003-02-14
BRPI0107737B8 (pt) 2021-05-25
DK1252322T4 (da) 2009-06-08
CY2016021I2 (el) 2016-12-14
JP6424145B2 (ja) 2018-11-14
BRPI0107736B8 (pt) 2021-05-25
EP2177619A1 (en) 2010-04-21
CA2398335A1 (en) 2001-07-26
ATE282708T1 (de) 2004-12-15
BRPI0107736B1 (pt) 2019-12-17
EP1252322B1 (en) 2004-11-17
US20120164108A1 (en) 2012-06-28
US8277818B2 (en) 2012-10-02
LU93101I2 (fr) 2016-08-08
US20200032219A1 (en) 2020-01-30
ES2233600T3 (es) 2005-06-16
FR16C0026I1 (nl) 2016-07-22
US7223593B2 (en) 2007-05-29
DE60107203D1 (de) 2004-12-23
AU2001226951B2 (en) 2006-10-05
DE60115600T2 (de) 2006-07-20
WO2001053506A3 (en) 2002-05-23
IL150678A0 (en) 2003-02-12
GB2375113B (en) 2004-10-20
US20120321599A1 (en) 2012-12-20
DE60107203T3 (de) 2009-07-23
DE60107203T2 (de) 2005-12-01
US20070003571A1 (en) 2007-01-04
CY2016020I1 (el) 2016-12-14
GB2374873C (en) 2011-07-27
CA2398335C (en) 2010-12-07
AU782659B2 (en) 2005-08-18
GB2374873B (en) 2004-05-26
FR16C0026I2 (fr) 2018-04-27
GB2374873A (en) 2002-10-30
PT1252322E (pt) 2005-03-31
BR0107736A (pt) 2002-11-19
US20090220460A1 (en) 2009-09-03
JP2015221813A (ja) 2015-12-10
HK1047297B (zh) 2004-10-21
ES2254359T3 (es) 2006-06-16
KR100768408B1 (ko) 2007-10-18
NL300821I2 (nl) 2016-10-27
IL150678A (en) 2008-12-29
HK1047451A1 (en) 2003-02-21
US20030113348A1 (en) 2003-06-19
ATE312189T1 (de) 2005-12-15
US20150232812A1 (en) 2015-08-20
EP1252323B1 (en) 2005-12-07
US20140154216A1 (en) 2014-06-05
US20070264282A1 (en) 2007-11-15
EP1252323A2 (en) 2002-10-30
JP4921669B2 (ja) 2012-04-25
AU2695101A (en) 2001-07-31
IL150677A (en) 2008-12-29
JP2019048864A (ja) 2019-03-28
LU93100I2 (fr) 2016-08-08
JP4810042B2 (ja) 2011-11-09
KR20020080383A (ko) 2002-10-23
GB2375113A (en) 2002-11-06
JP2003520044A (ja) 2003-07-02
CN1250732C (zh) 2006-04-12
ES2233600T5 (es) 2009-06-22
IL150677A0 (en) 2003-02-12
US20030091537A1 (en) 2003-05-15
EP1252322A2 (en) 2002-10-30
CY2016020I2 (el) 2016-12-14
EP1252322B2 (en) 2009-03-04
KR100802403B1 (ko) 2008-02-13
JP2017132779A (ja) 2017-08-03
HK1047451B (zh) 2005-03-18
JP2003520789A (ja) 2003-07-08

Similar Documents

Publication Publication Date Title
FR16C0026I1 (nl)
WO2003082200A3 (en) Potent oncolytic herpes simplex virus for cancer therapy
BR9912671A (pt) Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
ES2134346T3 (es) Virus citopatico para el tratamiento y la profilaxis de la neoplasia.
BR9712366A (pt) Gene de gd2 do vírus do herpes simples hsv2 isolado, plasmídeo compreendendo o mesmo, e, processos de induzir, em indivíduo, uma resposta imune contra hsv2 gd2, de tratar um indíviduo que está infectado com hsv, e, de prevenir que um indivíduo fique infectado com hsv
AU1550797A (en) Treatment of non-neuronal cancer using hsv mutant
DE69131200D1 (en) Herpes simplex virus vp16 impfstoffe
AU688101B2 (en) Live vaccine for the treatment of tumour diseases
ES2141093T3 (es) Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas.
GB2359083A (en) Mutant herpes simplex viruses and uses thereof
EP1550449A4 (en) ANTITUMORAL AGENTS WITH HSV
EP0401421A3 (en) Non-reverting rna viruses
AU6301398A (en) Arrestable therapeutic viral agent
Horstmann et al. Modified indication for surgery in AIDS associated gastrointestinal lymphomas
Saran et al. Palliative treatment of AIDS-associated kaposi's sarcoma by radiotherapy